长江商报消息 ●长江商报记者 徐靓丽 作为湖北省生物医药龙头企业，九州通（600998.SH）正大力推进战略转型，转向轻资产运作，并成为 A股+公募REITs"双上市"公司。 公司产品管线也在持续扩充。6月5日，九州通发布公告称，公司"倍他米松磷酸钠注射液"获得药品注册 证书，该药品获批上市有利于扩大其市场份额，助力公司医药工业自产业务持续、稳健发展。 九州通近年来积极拓展医药工业自产及OEM业务，2024年医药工业自产业务实现销售收入30.07亿元， 同比增长21.49%。其中，京丰制药2024年营业收入达5.92亿元，同比增长26.92%。 公司盈利能力也获得较大提升，2025年一季度公司实现归母净利润约9.7亿元，同比大增80.38%。 在新医疗上，九州通与腾讯云等合作，开发了"九医诊所AI辅助诊断平台"，赋能万家诊所及基层医疗机 构，构建起包括诊前智能导诊、诊中辅助诊断、智能审方、诊后慢病管理等的全流程运营体系，并借助 AI智能化工具为医生、患者提供服务，大大提高诊疗效率、保障处方安全、提升患者就诊体验。截至 今年3月末，"九医诊所"会员店已达1377家。 在不动产证券化（REITs）战略方面，九州通 ...

Core Viewpoint - The strategic transformation of the company, driven by the "Three New and Two Digital" strategy, has led to steady growth in performance, with significant increases in revenue and profit in 2024 and Q1 2025 [2][3][5]. Financial Performance - In 2024, the company achieved a total revenue of 151.81 billion yuan, a year-on-year increase of 1.11%, and a net profit attributable to shareholders of 2.507 billion yuan, up 15.33% [3][5]. - The net cash flow from operating activities turned positive at 3.083 billion yuan [3]. - For Q1 2025, the company reported revenue of 42.016 billion yuan, a growth of 3.82%, and a net profit of approximately 970 million yuan, an increase of 80.38% [4][5]. Business Segments - The core pharmaceutical distribution business showed stable growth, while emerging sectors like industrial self-production, OEM, traditional Chinese medicine, and digital logistics grew rapidly, each with a growth rate around 20% [3][4]. - The industrial self-production and OEM segment generated sales of 5.92 billion yuan, up 26.92%, with a gross margin of 42.48% [3]. - The traditional Chinese medicine segment achieved sales of 4.962 billion yuan, a growth of 18.14%, supported by a blockchain-based quality traceability platform [4]. Strategic Initiatives - The company is focusing on new product strategies, with sales from the pharmaceutical agency brand promotion business reaching 19.267 billion yuan, introducing 2,247 drug and device specifications [5][6]. - The new retail strategy has established over 29,000 franchise pharmacies, with B2C e-commerce sales reaching 980 million yuan and over 35 million end-users [5][6]. - The new medical strategy includes the development of an AI-assisted diagnostic platform in collaboration with Tencent Cloud, enhancing service efficiency for clinics and grassroots medical institutions [6]. Digital Transformation - The company invested 346 million yuan in digital and intelligent technology innovation, with 47 digital transformation projects implemented, 45 of which have been successfully launched [6]. - The logistics segment achieved revenue of 1.064 billion yuan, a growth of 25.32%, with a gross profit of 236 million yuan, up 17.08% [4]. Real Estate Investment Trusts (REITs) - The company completed the issuance of public REITs for its pharmaceutical warehousing and logistics, raising 1.158 billion yuan, marking a significant step towards asset-light transformation [7]. - The public REITs issuance saw a subscription multiple of 1,192 times, setting a historical record for public REITs [7].

当前，九州通正推进新产品、新零售、新医疗、数字化、不动产证券化的"三新两化"战略。新产品方 面，公司专门成立了四个研发机构，与多家科研院所建立合作，年研发费用2-3亿元，2024年前三季度 总代理实现销售141.19亿元，同比增长18%。 新零售方面，加盟药店已近30000家，2024年销售突破70 亿元，同比增长50%，已成为中国药品零售企业销售规模前十强。新医疗方面，已建立了"数字化+供应 链"体系，诊所加盟店达1366家，未来五年计划实现直营+加盟诊所突破万家。数字化方面，成立专门 领导小组和实施部门，拥有1400多名IT工程师，完成了100多个数字化项目。不动产证券化（REITs）， 2月27日，公司公募REITs在上交所发行成功，募集资金11.58亿元，成为行业第一支发行的医药仓储物 流资产公募REITs。 刘长云介绍，2020年九州通完成董事会换届，开启了从公司创始人向职业经理人团队过渡的转型之路， 目前运行良好。下一步将继续优化制度机制，真正建成现代化的公司治理体系，实现"百在老店"目标， 为湖北支点建设贡献力量。 极目新闻记者 庞正 4月17日，湖北举行全省民营经济发展大会，九州通医药集团董事 ...